UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/582,315	06/08/2006	Antonius Arnoldus Christiaan Jacobs	1-2003.025 US	1596
			EXAM	IINER
Patent Dept. K-	06/08/2006 Antonius Arnoldus Christiaan Jacobs 1-2003.025 US 1596 7590 11/23/2009 ering-Plough Animal Health K-6-1, 1990 SWARTZ, RODNEY P oing Hill Road			
2000 Galloping Hill Road Kenilworth, NJ 07033-0530			ART UNIT	PAPER NUMBER
			1645	
			NOTIFICATION DATE	DELIVERY MODE
			11/23/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

lakeisha.robinson@spcorp.com jill.corcoran@spcorp.com patents@spcorp.com

		Application No.	Applicant(s)			
Office Action Summary		10/582,315	JACOBS ET AL.			
		Examiner	Art Unit			
		Rodney P. Swartz, Ph.D.	1645			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)[\	7 Posponsivo to communication(s) filed on 24 July 2000					
· ·	Responsive to communication(s) filed on <u>24 July 2009</u> . This action is FINAL . 2b) This action is non-final.					
/—	· · · · · · · · · · · · · · · · · · ·					
<i>ا</i> ل	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
	closed in accordance with the practice under Ex parte Quayle, 1933 C.D. 11, 433 C.G. 213.					
Dispositi	on of Claims					
4)🛛	Claim(s) <u>1-15</u> is/are pending in the application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5)	Claim(s) is/are allowed.					
6)🖂	 ⊠ Claim(s) <u>1-15</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/or	election requirement.				
Applicati	on Papers					
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.03(a).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
<u> </u>						
	 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 					
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
* 0	* See the attached detailed Office action for a list of the certified copies not received.					
Gee the attached detailed Office action for a list of the certified copies flot received.						
Attachmen	t(s)					
	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ite			
	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application			

Application/Control Number: 10/582,315 Page 2

Art Unit: 1645

DETAILED ACTION

1. Applicants' Response to Office Action, received 24 July 2009, is acknowledged. Claims 1, 8, 9, 11 and 14 have been amended.

2. Claims 1-15 are pending and under consideration.

Rejections Withdrawn

- 3. The rejection of claims 1-15 under 35 U.S.C. 112, second paragraph, as being indefinite for "over-attenuated", is withdrawn in light of the amendment of the claims.
- 4. The rejection of claims 9 and 10 under 35 U.S.C. 112, second paragraph, as being indefinite for "derived", is withdrawn in light of the amendment of the claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Newly amended claims 1-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

As newly amended, the claims are drawn to a vaccine comprising a live, over-attenuated *O. rhinotracheal* strain which is not capable of inducing a protective immune response to *O. rhinotracheale* in animals primed with "a virulent pathogen".

According to this, indicator animals are primed with any virulent pathogen. However, the specification (lines 27-29) states that a primed animal is an animal that has received, prior to administration of the vaccine, a virulent pathogen that predisposes for infection with a secondary pathogenic bacteria.

Thus, the claims are drawn to any virulent pathogen for priming, while the definition of "over-attenuated" taught in the specification, is based on priming with a particular subgroup of virulent pathogens, i.e., those which predispose for infection with a secondary pathogenic bacteria.

Clarification concerning which type of priming pathogen is utilized for defining what is "over-attenuated".

Conclusion

- 6. No claims are allowed.
- 7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Wednesday from 9:00 AM to 7:30 PM EST. Thursday is the examiner's work at home day.

Application/Control Number: 10/582,315 Page 4

Art Unit: 1645

If attempts to reach the Examiner by telephone are unsuccessful, please contact the Examiner's Supervisor, Robert B. Mondesi (571)272-0956.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rodney P. Swartz, Ph.D./
Primary Examiner, Art Unit 1645
November 19, 2009